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Health technology assessment (HTA) methods and processes have been criticized for not 
being sufficiently ‘patient-centric’. For example, Perfetto (1) argued that a proposed 
approach for assessing the value of health care interventions had not sufficiently 
incorporated a patient perspective and suggested that it represented a ‘missed 
opportunity’. A similar point was made about the other ‘value assessment frameworks’ 
developed recently in the United States (2). In addition, Slejko et al (3) proposed some key 
elements of a ‘patient informed’ reference case for conducting economic evaluations, 
which would supplement reference cases outlined by groups such as the second Panel on 
Cost-Effectiveness in Health and Medicine (4), by including consideration of elements such 
as convenience in receiving care, effects on the patient’s family, examination of whether 
quality of life instruments include the most relevant domains and a model structure for 
the economic evaluation that adequately reflects the patient’s journey through the 
various treatment options. 
 
While the case to consider the patient perspective is strong, the way in which it should be 
incorporated in HTA is not obvious. Most HTA analysts would argue that HTAs, with the 
possible exception of some that are undertaken to support the development of clinical 
guidelines, or initiatives such as shared (clinical) decision-making, are conducted for those 
making decisions about the allocation of health care resources for a given population. This 
population may be the enrollees of a given health plan or, in the case of national health 
services or national insurance schemes, the whole population of a given country. The 
population would include patients who currently have the disease of interest, their 
families, those who have been patients in the past and those who may contract the 
disease in the future, as well as those past, present and future sufferers of other diseases. 
 
Of course, there may be considerable similarity between the perspective of patients 
currently suffering from a disease and the population at large, but this is not necessarily 
the case (5,6,7). Therefore, making HTA more patient-centric may not be as simple as it 
appears. The case for considering patient perspective may differ by type of health care 
system (8). For example, in a private insurance-based system, where a substantial 
proportion of the payments may be made directly by patients, one might expect more 
consideration of the patient perspective than in a publicly funded national health service. 
 
The empirical evidence generated in recent years shows that there is greater awareness 
about the importance of patients’ views in HTA, but there is no common understanding of 
what “patient-centric HTA” actually means (9). Here, we attempt to shed further light on 
the issue by conceptualizing “patient centricity” in two ways: 1) encouraging patients’ 
engagement in HTA process and 2) enlarging the scope of evidence in HTA to include 
patients’ outcomes and preferences (HTA methods).  We discuss the opportunities and 
challenges of each, by providing some recent examples from different countries. Finally, 
we discuss some additional ways to make HTA more patient-centric.  
 
Encouraging patient participation in HTA processes 
 
Many HTA organizations have made attempts to involve patients in their processes. This 
participation has taken many forms, including membership of committees, commenting 
on draft reports, inclusion in scoping exercises (to plan particular assessments) and 
citizens’ forums (to advise on particular ethical issues) (10,11). The main concern of 
patient organizations is that these initiatives are not as effective as they could be.  
 
First, the involvement of patients can best be described as ‘reactive’ rather than 
‘proactive’, in that by the time comments are requested on the results of particular HTAs 
it is often too late to re-visit the design of the study or the data collection. It is therefore 
important to involve patient organizations at an earlier stage, when it might be possible to 
influence the scope or methodology of the study (12). 
 
Secondly, the resources required to produce comments in a timely fashion, or to 
participate effectively on committees, are often beyond the reach of many patient 
organizations. Therefore, the influence of the patient perspective in HTA activities may be 
less that that of other stakeholders, such as the clinical professions or the healthcare 
industry. However, attempts have been made to increase the effectiveness of patient 
participation, such as the European Patients Academy (http://www.eupati.eu), where 
patient organizations can gain access to training on the key elements of HTA. 
  
 
Enlarging the scope of evidence in HTA 
 
 Incorporating  patient-reported measures in the development of ‘value frameworks’ 
 
There are currently relatively few examples of this, since in many jurisdictions there is a 
firm belief that population preferences, either direct or exercised through public decision-
making, should be the main driver of HTA. However, there may be opportunities for more 
patient involvement without infringing this more general principle. For example, in their 
argument for a ‘Patient-Informed Reference Case’, Slejko et al (3) argue that a societal 
perspective for economic evaluation, which is already adopted in some jurisdictions (eg 
Sweden), allows the consideration of patients’ costs. In addition, the ISPOR Value 
Assessment Framework for the US (13), while arguing the starting point should be an 
estimate of incremental cost per QALY, suggested that there should be more investigation 
of the measurement and incorporation of ‘novel’ elements of value.  
 
Many of these elements of value, such as impacts on work participation, increased 
convenience in receiving care, insurance value, the value of hope and impacts on 
caregivers, would be of direct interest to patients (14). Other authors argue that value 
“lies in the eye of the patient” (15), suggesting that patient-reported outcome measures 
(PROMs) are an invaluable source of data that can and should be used to inform HTA. The 
use of PROMs to support label claims for regulatory decision has been endorsed by FDA in 
the US, but there is still limited evidence of their use by HTA bodies. The same applies to 
complementary, patient reported experience measures (PREMs) which aim to capture 
elements such as route of administration of treatment, impact on caregivers and burden 
of disease. A recent literature review on use PREMs in 12 HTA bodies uncovered that only 
11% of HTA reports published after 2012 considered these measures to some extent (16).  
 
 
 Incorporating patient preferences in assessments of health technologies  
 
This probably the most contentious area of greater patient involvement. In Europe there 
are two main processes for making decisions about the adoption of new health 
technologies (17). The first approach, used in France and Germany, uses assessments of 
‘added clinical value’ based on an assessment of the clinical evidence for the technology 
concerned. It is not clear whose preferences are most influential in this approach and 
whether, when making assessments of added clinical value, clinicians mirror the 
preferences of patients. However, it may be possible for those making the decisions to be 
made aware the views of patients on the trade-offs between the various clinical endpoints 
being considered. 
 
The other approach, used in a number of Northern European countries, is to undertake 
assessments of the incremental cost-per quality-adjusted life-year (QALY) gained for new 
health technologies and to compare the ICER with a decision-making threshold, 
representing either the maximum willingness-to-pay for a given health gain, or the 
opportunity cost of the health displaced by discontinuing other treatments to make room 
(in the budget) to accommodate the new technology. In so far as preferences are used in 
this approach, they are normally the population-based health state preference values 
used in health-related quality-of-life instruments such as the EQ-5D. As in the clinical 
approach discussed above, it may be possible for those making the decisions to be made 
aware of the views of patients. This is already the case in some jurisdictions, through the 
presentation of patients’ experiences to the committee making the recommendations on 
the use of the treatment or technology. It may be also possible to use health state 
preference values based on the preferences of patients, but these are not often used to 
estimate the QALYs gained. 
 
Some of the preference measurement approaches, such as discrete choice experiments 
(DCEs) naturally lend themselves to more consideration of these additional dimensions 
than the standard approaches for estimating QALYs. However, their use in HTAs for 
decision-making has so far been limited (18). The reasons for this are not clear, although 
the standardization offered by QALYs is attractive to those decision-makers having to 
make a sequence of decisions, such as determining which treatments should be included 
on a ‘positive list’, or in the health insurance package. However, by their very nature, DCEs 
are often bespoke, whereas decision-makers often value standardization in their decision-
making procedures. Therefore, using these measures might be a challenge for those 
performing and using HTAs (19).  
 
However, it may be possible to standardize the attributes and levels used in DCEs in the 
healthcare field. It would also be possible to conduct DCEs with a representative sample of 
the general public, as opposed to patients. A European Union initiative, IMI-PREFER, seeks 
to establish recommendations to support guidelines for industry, regulatory authorities 
and HTA bodies on how and when to include patient perspectives on benefits and risks of 




Other approaches: recognizing patient heterogeneity by offering more choice 
 
Although the precise approach to decision-making differs across jurisdictions, the aim of 
HTA is to recommend a preferred course of action. Often this is a recommendation about 
the use of a particular health technology, but sometimes involves recommending a 
strategy for prevention, diagnosis or treatment. The definition of ‘preferred’ is sometimes 
unclear, but often means the strategy that is most clinical and cost-effective. One way of 
being more patient-centric would be to recognize that the preferred strategy might not be 
the same for all patients, because of heterogeneity in clinical characteristics or patient 
preferences. This would suggest that a choice of treatments could be offered, rather than 
a single ‘preferred’ treatment. 
 
In England, a jurisdiction where cost-effectiveness plays a central role in HTA 
recommendations, there are some examples where choice has been offered at additional 
cost, but within the threshold of ‘acceptable’ cost-effectiveness. For example, in a NICE 
clinical guideline on caesarian section it was recommend that women could request a 
planned caesarian section, rather than a vaginal birth, if after counseling they still had 
anxieties about childbirth (20). NICE also recommended that, instead of basal insulin 
therapy, patients with type 1 diabetes could be offered more expensive long-acting or 
quick-acting insulin therapy if twice-daily basal insulin therapy was not acceptable based 
on patient preferences (21). 
 
There may be other examples of offering choice, in situations where although there was 
an increase in cost, offering choice including the more expensive therapy was still within 
the acceptable range of cost-effectiveness. Another situation could be one where, in order 
to offer equal access to care for all patients, much greater costs would be incurred. For 
example, patients living in remote areas may need expensive transport to receive care, or 
may require other special provisions, such as mobile screening services. Even more 
controversially, treatments for patients with rare conditions may be more expensive to 
treat, so offering equal opportunity for care to these patients would have a substantial 
budgetary impact and consequent restrictions of care to other patients if the budget is 
fixed (22). Clearly, there a number of considerations in these cases, but there is a growing 
literature on how efficiency-equity choices could be addressed in conducting economic 





Should HTA be more patient-centric? The main driving force behind HTA should remain 
the preferences of the whole population served, whether this be the enrollees in a health 
plan, or the individuals having entitlement under national health insurance or health 
service. In these situations the provision of health care is largely funded collectively, 
although there are often some patient payments. Under conditions of collective funding it 
would be wrong to have health care provision driven by individual patients’ preferences, 
since this might run counter to collective wishes. Therefore, on occasions difficult choices 
are required to reconcile competing interests. In this editorial we argue that even within 
these constraints there are several initiatives than can be taken to make HTA more 
patient-centric. This can be done through encouraging patient engagement in HTA 
process, expanding the HTA methods to include patient-reported evidence, and other 
approaches, such as offering more choice, within the bounds of cost-effectiveness or 
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